KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 105 filers reported holding KEROS THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,873,662 | -46.9% | 341,081 | -33.1% | 0.93% | -53.1% |
| Q2 2023 | $20,470,143 | -36.5% | 509,461 | -32.5% | 1.98% | -19.8% |
| Q1 2023 | $32,243,581 | -19.5% | 755,119 | -9.5% | 2.47% | -4.8% |
| Q4 2022 | $40,048,344 | +19.9% | 833,993 | -6.0% | 2.60% | +20.1% |
| Q3 2022 | $33,391,000 | +26.7% | 887,592 | -6.9% | 2.16% | +63.6% |
| Q2 2022 | $26,354,000 | -43.6% | 953,801 | +11.1% | 1.32% | -36.1% |
| Q1 2022 | $46,698,000 | -4.6% | 858,730 | +2.7% | 2.07% | +20.0% |
| Q4 2021 | $48,938,000 | +62.7% | 836,398 | +10.0% | 1.72% | +81.6% |
| Q3 2021 | $30,081,000 | +18.3% | 760,383 | +27.0% | 0.95% | +31.1% |
| Q2 2021 | $25,434,000 | -10.2% | 598,880 | +30.1% | 0.72% | -12.7% |
| Q1 2021 | $28,336,000 | -24.8% | 460,372 | -13.9% | 0.83% | -29.1% |
| Q4 2020 | $37,705,000 | +253.1% | 534,514 | +93.1% | 1.17% | +257.2% |
| Q3 2020 | $10,677,000 | +3.5% | 276,827 | +0.7% | 0.33% | +5.1% |
| Q2 2020 | $10,315,000 | – | 275,000 | – | 0.31% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 396,911 | $21,584,000 | 5.10% |
| Deep Track Capital, LP | 1,380,306 | $75,061,000 | 4.81% |
| Opaleye Management Inc. | 265,750 | $14,451,000 | 4.49% |
| Octagon Capital Advisors LP | 340,214 | $18,501,000 | 4.00% |
| First Light Asset Management, LLC | 658,145 | $35,790,000 | 3.16% |
| Altium Capital Management LP | 126,000 | $6,852,000 | 2.29% |
| Nantahala Capital Management | 816,830 | $44,419,000 | 1.96% |
| Orbimed Advisors | 1,679,417 | $91,327,000 | 1.48% |
| CHI Advisors LLC | 62,229 | $3,384,000 | 1.44% |
| Parkman Healthcare Partners LLC | 72,690 | $3,953,000 | 1.16% |